Pawel Sobczuk
@pawel_sobczuk
MD PhD, Medical Oncologist, post-doc -at @VHIO, YOC Member & Communication Committee at @myESMO 🇵🇱🏳️🌈
ID: 1282270847865106433
12-07-2020 11:09:35
2,2K Tweet
1,1K Followers
637 Following
Can we identify factors related to risk of recurrence after neoadjuvant imatinib in GIST? - baseline tumor size, change on tx, mitotic index seems to identify high risk group - surprising no benefit of adjuvant tx —> need further validation ESMO - Eur. Oncology #ESMORareCancers25
